This information was published on 2022-02-17T16:51:25 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2248235 (IR 1643147) |
| (220) |
22 Sep 2021
|
| (300) |
US, 23 Mar 2021, 90596751
|
| (511) (510) |
Class 5
Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics; gene therapy products, namely, biological preparations based on engineered cells for medical use in immuno oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, including neurological disorders, huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, alzheimer's, parkinson's, ataxia, autism, epilepsy, pain, and also including cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders. Class 42 Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; molecular diagnostic services for medical research purposes. Class 44 Molecular diagnostic services for medical purposes; medical diagnostic testing services in the field of human disease and human medical conditions. |
| (540) | CRISPR BY DESIGN |
| (550) | Word |
| (730) |
Scribe Therapeutics Inc.
|
Find out more about publications on the About page.